27 results on '"Durn, Billie L."'
Search Results
2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
3. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
4. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti‐blood group A and B antibodies and individual susceptibility
5. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials
6. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
7. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy
8. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
9. Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
10. 17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study
11. 18. Secondary endpoints (PATH extension study): Long-term outcomes of subcutaneous immunoglobulin IgPro20 in CIDP maintenance treatment
12. 21. Exposure-response of serum IgG levels and INCAT scores in CIDP patients receiving subcutaneous immunoglobulin (IgPro20)
13. 19. Pharmacokinetic modelling and simulation of flexible dosing regimens of subcutaneous immunoglobulin (IgPro20) in CIDP patients
14. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
15. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in CIDP: the PATH Study (S43.004)
16. Placebo Effect in the PATH Study of Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (S43.006)
17. Long-term Safety and Efficacy of Subcutaneous Immunoglobulin IgPro20 in CIDP: the PATH Extension Study. (S43.005)
18. Analysis of Relapse by MRC Sum Score in the PATH Study of Subcutaneous Immunoglobulin in CIDP (P5.2-076)
19. Treatment Satisfaction and Work Productivity in a Clinical Study of IgPro20 Maintenance Treatment of CIDP (P5.2-078)
20. Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
21. 046 Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP)
22. Intravenous versus subcutaneous immunoglobulin – Authors' reply
23. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
24. Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase III b Clinical Trials
25. Intravenous versus subcutaneous immunoglobulin – Authors' reply
26. Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding
27. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna® immunoassay system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.